A major Alzheimer’s risk gene may shrink brain cells years before symptoms

For decades, medical researchers have understood that genetics play a profound role in the development of Alzheimer’s disease, a progressive neurodegenerative disorder that currently affects millions of individuals globally. Among the recognized genetic markers, the apolipoprotein E (APOE) gene has long been established as a primary determinant of risk. Specifically, the APOE4 variant stands out as the most potent known genetic risk factor for the late-onset form of the disease. Approximately one-quarter of the general population carries at least one copy of the APOE4 allele, and its prevalence is strikingly high among diagnosed patients, appearing in an estimated 60 to 75 percent of all Alzheimer’s cases.

Despite this well-documented epidemiological link, the exact molecular mechanisms by which APOE4 exerts its detrimental effects have remained stubbornly elusive. For years, scientists debated whether the gene variant’s impact was mediated primarily through supporting cells in the brain or via direct action within neurons themselves. Now, a groundbreaking study conducted by researchers at the Gladstone Institutes and recently published in the peer-reviewed journal Nature Aging sheds vital light on this mystery. The new research maps out a precise molecular sequence that explains how APOE4 alters brain activity decades before clinical symptoms manifest, while simultaneously pointing toward a promising therapeutic pathway capable of reversing these early cellular abnormalities.

Tracing the Chronology of Cognitive Decline

To understand the trajectory of Alzheimer’s disease, researchers must look far upstream from the moment memory loss or cognitive impairment becomes clinically apparent. Clinical observations have long noted that human carriers of the APOE4 variant often exhibit subtle anomalies in brain function—specifically, regions of hypermetabolism and excessive electrical activity—well before entering middle age. Historically, however, researchers struggled to connect these early functional shifts directly to subsequent cognitive decline due to the limitations of human brain imaging and the slow progression of neurodegeneration over decades.

To bridge this knowledge gap, the Gladstone research team embarked on a detailed, age-stratified investigation using advanced murine (mouse) models. By recording and analyzing brain activity across different developmental stages, the investigators were able to construct a chronological timeline of how APOE4 impacts neurological health.

In young mice carrying the human APOE4 gene, the researchers observed premature and excessive neuronal firing concentrated in two specific subregions of the hippocampus, a seahorse-shaped brain structure universally recognized as critical for spatial navigation, learning, and the formation of new memories. Crucially, these hippocampal regions correspond precisely to the areas identified as hyperactive in human APOE4 carriers during functional neuroimaging studies.

Furthermore, the team established a direct predictive correlation: the degree of neuronal hyperactivity recorded in young mice served as an accurate bellwether for cognitive performance later in life. Animals that exhibited the most severe electrical hyperactivity in their youth invariably performed the worst on standardized spatial learning and memory tests as they aged. Conversely, control mice carrying the APOE3 gene—a common variant associated with neutral or protective effects against Alzheimer’s—did not develop this accelerated neuronal excitability until they reached advanced chronological age. This timing disparity strongly indicates that the APOE4 variant does not merely cause random damage; rather, it drastically accelerates biological processes that mirror normal neural aging, precipitating cognitive vulnerability much earlier in the lifespan.

Shifting the Paradigm: The Intracellular Source of APOE4 Toxicity

For many years, the prevailing scientific consensus regarding APOE expression focused on glial cells, particularly astrocytes. In a healthy adult brain, astrocytes are the primary producers of apolipoprotein E, supplying lipids and metabolic support to neurons. Because of this division of labor, neuroscientists long hypothesized that the pathological consequences of APOE4 originated externally, with astrocytes releasing the faulty protein into the extracellular matrix where it would subsequently disrupt surrounding neural networks.

However, the Gladstone study challenges this long-held dogma by revealing that the hippocampal hyperactivity associated with APOE4 is driven entirely by protein produced within neurons themselves, rather than by neighboring astrocytes.

To arrive at this conclusion, the research team performed targeted genetic deletions in their experimental models. When the scientists knocked out the APOE4 gene specifically within astrocytes, the abnormal neuronal firing persisted unabated, and cellular morphology remained unchanged. In stark contrast, when they deleted the APOE4 gene specifically within the neurons, the physiological phenotype shifted dramatically: the affected neurons expanded back toward normal dimensions and resumed standard electrical firing patterns.

This intracellular mechanism alters the strategic focus for drug developers. Rather than attempting to neutralize extracellular APOE4 floating in the brain’s interstitial fluid, future interventions may need to concentrate on modifying or blocking the expression of the gene variant inside the neuron itself.

The Discovery of Nell2 as a Molecular Driver

Having identified the intracellular origin of APOE4-induced neuronal dysfunction, the research team sought to pinpoint the exact downstream molecular cascade responsible for making neurons smaller and hyper-excitable. By performing high-resolution gene expression profiling at the single-cell level across various cellular populations within the hippocampus, the investigators identified a critical culprit: a protein known as neural epidermal growth factor-like 1 (Nell2).

In neurons carrying the APOE4 variant, levels of Nell2 were found to be abnormally elevated. This overexpression correlated directly with morphological changes; the affected neurons were consistently smaller than their APOE3 counterparts. In neurobiology, smaller cellular volume alters surface-area-to-volume ratios, increasing input resistance and making individual neurons hypersensitive to incoming chemical and electrical stimuli. This structural vulnerability lowers the threshold for firing, ultimately driving the network-wide hyperactivity observed in the hippocampus.

To test whether Nell2 was merely a passive biomarker or the active driver of this pathology, the researchers employed CRISPR interference (CRISPRi), an advanced molecular technique that allows scientists to selectively downregulate gene expression without making permanent, irreversible alterations to the underlying DNA sequence. Using CRISPRi, the team successfully reduced Nell2 expression levels in the hippocampal neurons of adult APOE4 mice.

The results of this intervention were striking. Following the reduction of Nell2, the abnormally small neurons expanded back toward their normal physical dimensions, and their hyperactive firing behaviors normalized. Although Nell2 had not previously been heavily investigated in the context of APOE genetics, earlier independent studies had noted elevated concentrations of the protein in post-mortem brain tissue from Alzheimer’s patients, with higher concentrations generally correlating with poorer cognitive performance during life.

Implications for Therapeutic Development and Future Research

The discovery that lowering Nell2 can restore normal physiological function in adult murine models carries profound implications for the future of Alzheimer’s disease therapeutics. Most current pharmacological approaches in clinical trials focus on clearing pathological protein aggregates, such as amyloid-beta plaques and tau tangles, which accumulate late in the disease process when significant and often irreversible neurodegeneration has already occurred.

By contrast, the findings from the Gladstone Institutes suggest an opportunity for early intervention that targets upstream functional abnormalities before structural brain damage becomes permanent. The fact that genetic or molecular reversal was successfully achieved in adult mice indicates that the neurological system retains a degree of plasticity, and that the damage inflicted by APOE4 is not inherently locked in stone once initiated.

Principal staff research scientist Dr. Misha Zilberter, a senior author of the study, emphasized the pioneering nature of the work. To the research team’s knowledge, this represents the first direct examination of how the APOE4 variant functionally alters neuronal properties across different age brackets, establishing a clear link between early circuit-level shifts and subsequent cognitive decline.

Echoing this sentiment, Dr. Yadong Huang, associate director of the Gladstone Institute of Neurological Disease and co-senior author of the study, highlighted the broader significance for the scientific community. According to Dr. Huang, the findings open a vital new chapter in neurodegeneration research by clarifying how a genetic variant alters neuronal function early in life, thereby laying the groundwork for preventive pharmacological therapies capable of neutralizing APOE4 toxicity long before clinical symptoms emerge.

As the scientific community digests these findings, researchers are already looking toward the next phases of translational development. Future efforts will likely focus on designing pharmacological compounds or gene-silencing therapies that can safely and specifically target the Nell2 pathway in humans. While moving from mouse models to human clinical trials involves rigorous safety and efficacy testing, this study provides a concrete roadmap, transforming an elusive genetic risk factor into a tangible, actionable target for intervention in the global fight against Alzheimer’s disease.